Monograph
N02CC05 - Almotriptan |
Propably not porphyrinogenic |
PNP |
Rationale
Probably not affecting hepatic CYPs.
Therapeutic characteristics
Vascular 5HT-receptor agonist used in migraine.
Metabolism and pharmacokinetics
Eliminated by oxidative deamination via monamine oxidase. CYP 3A4 and2D6 are alo involved in its metabolism. In vitro studies show that almotriptan is not expected to affect the metabolism of CYP-metabolized drugs.
Personal communication
Badminton M (2006): Almotriptan has been used without any adverses effects in a 17 yr old female with VP (no previous attacks).
IPNet drug reports
One report of a possible beginning of an acute porphyric attack in a susceptible female with AIP, but the attack was poorly documented and several other factors could explain the symptoms. This report has therefore not been taken into account in the judgement of the porphyrinogenicity of almotriptan. Uneventful use reported in 1 patients with acute porphyria.
Similar drugs
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Almogran · Almotriptan 
Almogran 
Almogran · Almotriptan · Amignul · Riptanax 
Almogran · Almotrex · Almotriptan 
Almogran · Almotriptan 
Almogran · Almotriptan 
Almogran · Almotriptan 
Almozen · Dezamigren · Nomigren · Trymigan 
Almogran 
Almogran 
Almogran 
Almotriptan
© NAPOS 2025